Objective To explore the clinical effect of rivaroxaban anticoagulant therapy against chronic obstructive pulmonary disease complicated with pulmonary hypertension.Methods In this study, the clinical data on 163 patients with COPD complicated with pulmonary hypertension admitted to our hospital between January 2016 to January 2018 was collected. Such information as the age, gender, body mass index, 6-minute walk test, NT-proBNP, blood analysis, lung function, arterial blood gas analysis and heart color ultrasound of the patients was collected. The control group was given the routine oxygen therapy as well as anti-inflammatory, phlegm-reducing and antiasthmatic treatment, while the treatment group additionally received rivaroxaban 10mg/day oral anticoagulant therapy.Results of cardiac ultrasound, arterial blood gas analysis and 6-minute walking test were compared between the two groups after 30 days of treatment. The data on pulmonary artery pressure, 6-minute walking distance, arterial oxygen partial pressure and carbon dioxide partial pressure in both groups was statistically analyzed.Results Pulmonary arterial pressure decreased significantly in the experimental group after rivaroxaban anticoagulant treatment compared with the control group[(32.7±3.8) vs(51.2±2.7),(P<0.05)]. The 6-minute walking distance of the experimental group was significantly increased compared with the control group[(467.7±5.4) vs (397.8±4.8),(P<0.05)]. The partial pressure of arterial oxygen in the experimental group was significantly higher than that of the control group[(75.6±3.7) vs (63.7±4.5),(P<0.05)]. Arterial partial pressure of carbon dioxide decreased significantly compared with the control group[(43.6±3.7) vs(49.7±2.9)]. The above indexes in the experimental group were significantly improved compared with the control group, and the difference was statistically significant.Conclusions Rivaroxaban anticoagulant therapy has a good clinical effect on chronic obstructive pulmonary disease complicated with pulmonary hypertension, It can improve the quality of life and prognosis of patients.
Key words
chronic obstructive pulmonary disease /
pulmonary hypertension /
rivaroxaban /
6 minutes walk test /
partial pressure of arterial oxygen /
arterial partial pressure of carbon dioxide
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
[1] Wang C,Xu J Y,Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China pulmonary healthstudy):a national cross-sectional study[J].Lancet,2018,391(10131):1706-1717.
[2] Marc D, Wim J, Yang L,et al. Chronic obstructive pulmonary disease[J]. Lancet, 2012,379(9823): 1341-1351.
[3] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013 年修订版)[J].中华结核和呼吸杂志,2013,36(4):255-264.
[4] 中华医学会心血管病学分会肺血管病学组,中华心血管病杂志编辑委员会.中国肺高血压诊断和治疗指南 2018[J].中华心血管病杂志,2018,46(12):933-964.
[5] 董绍臣,于鸿敏,赵冬梅,等.嗜酸性粒细胞高低对慢性阻塞性肺疾病急性加重期是否应用激素的指导价值[J].武警医学,2020,31(2):114-117.
[6] 王 辰,杜敏捷,曹大德,等.慢性肺原性心脏病急性发作期肺细小动脉血栓形成的病理观察[J].中华医学杂志,1997,77(2):123-125.
[7] 李 蕾. COPD合并肺栓塞和AECOPD患者凝血功能、肺动脉收缩压及动脉血气分析的差异[J].江苏医药,2016,42(8):962-963.
[8] Shi Xiaoshan, Li Hongyun. Anticoagulation therapy in patients with chronic obstructive pulmonary disease in the acute exacerbation stage[J].Exp Ther Med,2013,5(5):1367-1370.
[9] Erhan U, Emine K T, Llknur C, et al. Impaired hemorheology in exacerbations of COPD[J].Can Respir J,2017,9:1286263.
[10] 苏冠春. 氯吡格雷对慢性阻塞性肺疾病急性加重 期血液高凝状态及肺功能的影响[J]. 国际老年医学杂志,2019,40(2):75-77.
[11] 张谨超,崔月娥,刘 娜,等.利伐沙班和低分子肝素治疗老年慢性阻塞性肺疾病急性加重期的效果观察[J].中国医药,2019,14(4): 533-536.
[12] 伍 涛.低分子肝素对慢性阻性肺疾病急性加重期的临床疗效观察[J].世界临床医学,2017,11(2):2-5.
[13] 陈春玲.华法林抗凝疗法在慢性阻塞性肺疾病急性加重期患者中安全性和有效性分析[J].徐州医科大学学报,2019,39(5):346-349.
[14] 邹 毅.AECOPD患者的凝血功能,肺功能状况及华法令抗凝治疗分析[J].湖南师范大学学报(医学版),2020,17(4):131-133.
PDF(666 KB)
